Adenovirus News and Research RSS Feed - Adenovirus News and Research

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.
Study reveals causes of community-acquired pneumonia in children

Study reveals causes of community-acquired pneumonia in children

With the chill of winter comes a spike in community-acquired pneumonia (CAP), which spreads more easily as people retreat indoors and come into close contact. The lung infection triggers persistent coughing, chest pain, fever, and difficulty breathing, and is particularly hard on the very young and the very old. In fact, pneumonia is the leading cause of hospitalization among U.S. children, with estimated medical costs of $1 billion annually. [More]
Study points respiratory viruses as the most common cause of childhood pneumonia

Study points respiratory viruses as the most common cause of childhood pneumonia

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine. [More]
Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

AMSBIO reports on the recent publication in Cell [1] by Dr Meritxell Huch, Prof Hans Clevers et al. of ground-breaking research using Cultrex BME2 reduced growth factor (organoid growth matrix) to enable long-term (>1 year) culture of genome-stable bipotent stem cells from adult human liver. These results open up new experimental avenues towards the use of human liver material expanded in vitro as an alternative cell source for disease modeling, toxicology studies, drug testing, regenerative medicine and gene therapy. [More]
Efficacy of ebola vaccine to be assessed in large-scale clinical trial

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine. [More]
NCCS launches human clinical trial of new cancer vaccine

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years. [More]
Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

AMSBIO has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB™ brand. [More]
Antigens and antibodies for an optimised ELISA test kit for Ebola

Antigens and antibodies for an optimised ELISA test kit for Ebola

AMSBIO has announced several products suitable for the development of an ELISA detection assay for the Ebola virus. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro- a new generation transfection reagent developed specifically for maximum nucleic acid delivery into neurons, typically achieving a 2-fold or greater improvement in efficiency over currently available competing reagents. [More]
CRISPR/Cas9 genome editing: an interview with Maja Petkovic

CRISPR/Cas9 genome editing: an interview with Maja Petkovic

RNA guided CRISPR nucleases have a great potential for genome modification in many different organisms. [More]
Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy. [More]
Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

AMSBIO, experts in extracellular matrices, have introduced the Cultrex® Embryoid Body Formation Kit to generate consistent, reproducible and identical in size embryoid bodies. It has been qualified to form embryoid bodies from human pluripotent stem cells. Embryoid bodies are finding increasing use in regenerative medicine, in-vitro screening and as a model of embryonic development. [More]
Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland. [More]
Research shows that copper could help to prevent Ebola spread

Research shows that copper could help to prevent Ebola spread

Research from the University of Southampton has indicated that copper could help to prevent the spread of Ebola. [More]
ADI develops ELISA test kits for detection of Ebola viral protein antibodies

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40). [More]
First study of promising Ebola vaccine commenced in West Africa

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine. [More]
Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. [More]
SLU researchers work to prevent several serious infectious diseases

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences. [More]
Experimental vaccine protects monkeys exposed to Ebola virus

Experimental vaccine protects monkeys exposed to Ebola virus

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators. [More]
Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer. [More]